Johnson & Johnson (JNJ) said Monday it will present the latest data from the TAR-200 study to treat patients with Bacillus Calmette-Guerin-unresponsive, high-risk non-muscle-invasive bladder cancer with carcinoma in situ with or without papillary disease at the American Urological Association on April 26.

The 12-month duration of response findings from cohort 2 of the phase 2b trial evaluating the TAR-200 monotherapy revealed a positive complete response rate, according to a statement.

The company said it will also present the first results from cohort 4 of the phase 2b trial for patients with papillary-only, high-risk non-muscle invasive bladder cancer.

Price: 157.83, Change: +0.35, Percent Change: +0.23